The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.
- About the CF Foundation
- Public Policy
- Drug Pipeline
- CFTR Modulators
- Our Research Approach
- Genetic Therapies
- Health Care Reform
- Clinical Trials
- Get Involved
- Our Advocacy Work
- North American CF Conference
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Care Centers
- Patient Assistance
- Infection Prevention and Control
- Patient Registry
- Coronavirus (COVID-19)
- Lung Transplantation
- In the Spotlight
- Diversity, Equity, and Inclusion
- Intro to CF
- Adult Care
- Clinician Resources
- Great Strides
- In Memoriam
- Researcher Resources
- Care Team
- CF-Related Complications
- CF Related Health Conditions
- Fertility and Reproductive Health
Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
With this approval, approximately 2,250 children in the U.S. will be eligible for Trikafta® (elexacaftor/tezacaftor/ivacaftor), including more than 900 who will have access to a CFTR modulator for the first time. The Cystic Fibrosis Foundation believes it is beneficial to start people with cystic fibrosis on modulators as early as possible to help prevent lung damage and the onset of complications.
Proposed policies would impose significant barriers and add burden for people with CF
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
Funding will support clinical trials for therapy that could help improve digestion in people with CF
Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
Delivery of genetic therapies to affected tissues is a key challenge to developing new treatments for people with cystic fibrosis. In addition to investing in viral delivery and lipid nanoparticles, the Cystic Fibrosis Foundation is looking at the potential of a relatively new approach to delivery using an exceptionally small synthetic molecule called a polymer nanoparticle.